Browse Articles
Discover research articles across all indexed journals
10 recommendations for strengthening citizen science for improved societal and ecological outcomes: A co-produced analysis of challenges and opportunities in the 21st century
Citizen science plays an increasingly important role in generating scientific knowledge and supporting environmental and social action. However, its potential to address complex global challenges remains underutilised. This study explores how citizen science can be improved by involving the public in all stages of scientific research. Using participatory research methods, online surveys and group discussions were conducted with researchers, citizen scientists, and Indigenous participants. Thematic coding was used to identify key challenges, opportunities, and best practices to enhance citizen science initiatives. Additionally, nine case studies were reported using the Standardised Data on Initiatives (STARDIT) reporting tool. The study identified key strategies for improving involvement, engagement and retention in citizen science initiatives. Findings underscore the importance of inclusive, evidence-informed approaches such as targeted outreach, fair compensation, tailored support, and co-creation practices. Ensuring data quality and fostering trust require adherence to FAIR data principles (findable, accessible, interoperable and reusable), transparent validation and sharing processes, and establishing ethical research partnerships. Persistent challenges include short-term funding, which undermines long-term project sustainability, and the lack of centralised support for ethics and project management. Formal recognition of citizen scientists through co-authorship, standardised training, and professional development opportunities can further strengthen involvement and build capacity. Finally, emerging technologies, including artificial intelligence and open data platforms, present opportunities to scale and improve efficiency, provided they are implemented with appropriate ethical safeguards and investment. Drawing together these insights, we provide 10 actionable recommendations for citizen science in the 21 st century. These highlight the importance of embedding citizen science in national research infrastructure, education, and policy, alongside consistent evaluation and reporting, to improve its inclusivity, longevity, and impact. We conclude by arguing that as the world confronts climate change, public health crises, and biodiversity loss, broader public involvement in science is key for equitable, efficient and evidence-informed responses.
Programmable In Vivo Synthesis of Quantum Dots
ABSTRACT In vivo synthesis of quantum dots (QDs) is fundamentally hindered by the inability to control the spatiotemporal coupling of ionic precursors in living organisms. Herein, we present a s patially h ierarchical i ntegrated n anosynth e sizer (SHINE, FtAg@SS/SiO 2 ‐Se) for the programmable biosynthesis of silver selenide (Ag 2 Se) QDs within tumors. The SHINE integrates a ferritin encapsulating silver source with a custom‐synthesized selenium source, localized on a physically isolated glutathione (GSH)‐responsive silica shell doped with disulfide bonds. Crucially, the thickness of such a shell has provided precise trigger time control over the synthesis. Upon entry into the tumor microenvironment, the elevated GSH triggers a sequential cascade: cleavage of the diselenide bonds generates reactive selenium species, followed by rupture of the silica shell to release the silver‐loaded ferritin, thereby enabling spatially and temporally controlled in situ synthesis of Ag 2 Se QDs. The SHINE has been validated for high‐contrast bioimaging in the second near‐infrared window in live mice. Furthermore, the synthesis process and the resulting QDs orchestrate a synergistic antitumor effect by depleting GSH to enhance oxidative stress and conferring potent photothermal conversion, leading to significant tumor suppression. This work establishes a generalizable strategy for the controlled fabrication of functional nanomaterials in vivo.
Changes in stomatal density and leaf area per mass induced by sunlight acclimation in Bertholletia excelsa and Carapa guianensis
An Inorganic Layered Coordination Polymer as High‐Performance Solid‐State Electrolyte for Stable Lithium Metal Batteries
ABSTRACT Limited ionic conductivity, heterogeneous Lithium‐ion flux, and interfacial instability in solid‐state electrolytes (SSEs) hinder the development of high‐energy‐density solid‐state lithium metal batteries (SSLMBs). Herein, we report a new Li + conducting SSE derived from an inorganic coordination polymer, specifically a two‐dimensional Hofmann‐type framework material (HFM). By varying the solvent types used as interlayer guest molecules, we can modulate the interlayer spacing of the HFM. Specifically, when methoxymethane (DME) serves as the guest, it orchestrates highly selective Li + transport pathways within the structure, achieving a high ionic conductivity of 1.51 mS cm −1 . The coordination between metal centers and solvent molecules leads to the reconstruction of the local Li + solvation structure, effectively immobilizing solvent molecules and lowering the energy barriers for the desolvation process. More importantly, a Li 3 N‐rich solid electrolyte interphase forms on the lithium anode, stabilizing the Li–electrolyte interface. As a result, Li||Li symmetric cells demonstrate stable cycling for over 3000 h, while LiFePO 4 ||Li full cells show a capacity retention of 96.3% after 500 cycles at 1C. This work establishes a structurally nanoconfined electrolyte system that bridges ion‐selective nanochannels with a stabilized interphase, offering a promising platform for next‐generation high‐energy‐density SSBs.
Kinetic model of partial agonism reveals cellular basis of ligand efficacy
Rapid and reversible endothelial glycocalyx injury during tyrosine kinase inhibitor therapy in locally advanced or metastatic renal cell carcinoma.
192 Background: Endothelial glycocalyx, which coats the luminal surface of vascular endothelial cells, plays a pivotal role in maintaining vascular homeostasis by regulating thrombogenicity, modulating inflammatory responses, and preserving endothelial barrier integrity. Tyrosine kinase inhibitors (TKIs) are associated with vascular toxicities, yet their impact on endothelial glycocalyx integrity remains unclear. Because glycocalyx disruption is an early event in endothelial dysfunction, we investigated whether TKI therapy induces endothelial glycocalyx injury in patients with locally advanced or metastatic renal cell carcinoma (mRCC). Methods: In this retrospective study, 25 patients initiating and 24 patients discontinuing TKIs (axitinib, cabozantinib, lenvatinib, or pazopanib) due to adverse events were analyzed. Plasma hyaluronan levels, a validated biomarker of endothelial glycocalyx injury, were measured before and 1 month after TKI initiation or discontinuation using enzyme-linked immunosorbent assay. Paired comparisons were performed using the Wilcoxon signed-rank test. Differences among agents were evaluated using the Kruskal–Wallis test. Results: Among patients initiating TKIs, plasma hyaluronan levels significantly increased at 1 month (median 117 vs. 218 ng/mL; +75%; P <0.001). No significant differences were observed among the four agents ( P = 0.922). Conversely, in patients discontinuing TKIs due to adverse events, plasma hyaluronan levels significantly decreased (median 221 vs. 135 ng/mL; −37%; P <0.001), without inter-agent differences ( P = 0.865). Conclusions: TKI therapy is associated with rapid and reversible endothelial glycocalyx injury in patients with locally advanced or mRCC. These findings suggest a potential mechanistic link between TKI exposure and vascular toxicity across agents.
Genomic enrichment using Decipher and PAM50 luminal B to optimize neoadjuvant immunotherapy strategies in high-risk prostate cancer.
197 Background: Clinical risk tools incompletely capture biologic heterogeneity in prostate cancer (PCa), limiting enrichment for neoadjuvant trials. We evaluated whether integrating Decipher genomic risk with PAM50 luminal B subtype identifies a clinically aggressive and immunologically distinct subset suitable for biomarker-enriched therapeutic intensification. Methods: We analyzed 807 men undergoing radical prostatectomy with clinical Decipher testing. Marker-positive tumors were defined as Decipher intermediate/high/very high risk combined with PAM50 luminal B. Associations with biochemical recurrence (BCR) and distant metastasis (DM) were assessed using multivariable Cox models. Validation was performed in a commercial cohort (n=54,567). Pathway and immune signatures were evaluated. Multiplex immunohistochemistry was performed in paired pre-treatment biopsy and post-treated prostatectomy specimens from 15 marker-positive patients receiving neoadjuvant ADT ± AR signaling inhibitors. In vivo efficacy was assessed in MyC-CaP models treated with ADT + darolutamide + pembrolizumab. Results: Marker-positive tumors comprised 28.7% (232/807) of the cohort and were enriched for adverse pathology (81% vs 46%, p<0.001). BCR occurred in 38% vs 25% and DM in 19% vs 9% of marker-positive versus marker-negative high risk patients (both p<0.001), reflecting approximately two-fold metastasis enrichment. Marker-positive status independently predicted DM (HR 1.87, p=0.003). Marker-positive tumors demonstrated enrichment for PTEN loss, p53 mutation, and cell cycle progression signatures. Paired specimens demonstrated significant post-treatment increases in CD4+ and CD8+ T cells and PD-1/PD-L1–positive immune cells. In MyC-CaP models, ADT + darolutamide + pembrolizumab increased CD3+ infiltration and checkpoint expression compared with control and reduced tumor growth relative to monotherapy arms. Conclusions: Integrated Decipher and luminal B stratification identifies a biologically aggressive PCa subset with approximately two-fold higher metastasis risk and enrichment for immune-modifiable biology. These findings provide the rationale for an ongoing investigator-initiated phase II neoadjuvant trial of ADT + darolutamide + pembrolizumab followed by adjuvant pembrolizumab in molecularly selected high-risk PCa (GC>0.45 + luminal B; NCT07027124), with minimal residual disease (≤0.25 cm³) as the primary endpoint.
A deep learning framework for efficient pathology image analysis
Abstract Artificial intelligence has transformed digital pathology by enabling biomarker prediction from high-resolution whole-slide images. However, current methods are computationally inefficient, processing thousands of redundant tiles per slide and requiring complex aggregation models. We introduce EAGLE (Efficient Approach for Guided Local Examination), a deep learning framework that emulates pathologists by selectively analyzing informative regions. EAGLE combines task-agnostic tile selection with detailed feature extraction and is benchmarked against leading slide- and tile-level foundation models across 43 tasks from nine cancer types spanning morphology, biomarker prediction, treatment response and prognosis. EAGLE outperforms patch aggregation methods by up to 23% and achieves the highest overall classification performance. It processes one slide in 2.27 s, reducing computational time by more than 99% compared with existing models. This efficiency supports rapid and auditable workflows by enabling review of the exact tiles used for each prediction and reducing dependence on high-performance computing. By reliably identifying informative regions and minimizing artifacts, EAGLE provides robust and auditable outputs, supported by systematic negative controls and attention concentration analyses. Its unified embedding enables rapid slide search, integration into multi-omics pipelines and emerging clinical foundation models.
Stereoretentive and Regioselective Late-Stage C–H Glycosylation
Silenced and privileged voices in media discourses: Climate change and social capital
Media representations and narratives around climate change are often dominated by certain voices whilst others are excluded or marginalized. This study investigates media portrayal of climate change around Glasgow’s COP26, focusing on the prominence or exclusion of certain voices. Analyzing US and UK newspaper coverage, it identifies variances in representation, with Indigenous and minority voices marginalized in favor of political, scientific, and activist perspectives from the Global North. Through content analysis, the research explores how power, access, and frames shape media narratives on climate change, underscoring the need for more inclusive discussions.
High Resistivity and Low Defect Covalent Organic Frameworks for Highly Stable and Low Dose X‐Ray Detection
ABSTRACT Direct x‐ray detection technology has long been constrained by trade‐offs between the extracted charge‐carrier signal and mobile‐metal‐ion noise under applied electric fields in conventional semiconductor materials. Here, we report the first demonstration of a low‐defect covalent organic framework (COF)‐based direct X‐ray detector, employing COF366‐M (M = Co, Cu) as the active layer. By incorporating metal ions into a porphyrin‐centered crystalline framework linked through multiple coordinate bonds, COF366‐M enhances x‐ray attenuation while effectively preventing ion migration with negligible current drift of ∼10 −18 A·cm −1 ·V −1 ·s −1 under the operating electric fields. The highly ordered nanochannels in COF366‐M exclude unintended ion doping and exhibit high resistivity along with a low defect level suitable for x‐ray detection. The addition of carbon nanotubes (CNTs) further enhances electron‐hole separation and creates charge‐transport pathways. The device achieves a high sensitivity of up to 11,784 µC·Gy −1 ·cm − 2 , a low detection limit of 39 nGy·s −1 , and excellent operational stability, with no degradation after a high cumulative x‐ray dose of 148 Gy. Moreover, the fully environment‐friendly composition ensures intrinsic environmental friendliness. This work not only validates COFs as a promising platform for high‐performance, stable, and green x‐ray detection, but also provides a molecular‐level paradigm for designing next‐generation low‐dose radiation sensing materials.
Influencing factors and prediction of creativity among college students in traditional Chinese medicine schools: network analysis
Intrinsically Stable Amorphous Phases Unlock Sustainable Potassium Anodes
ABSTRACT Non‐graphite‐based anodes for potassium‐ion batteries offer high capacity but suffer from severe structural degradation due to repeated phase transitions during cycling. Here, we introduce an amorphous phase engineering strategy that fundamentally addresses this instability. The intrinsic structural isotropy and open framework of amorphous materials inherently mitigate volume strain, enabling exceptional long‐term cycling stability. As a proof of concept, an amorphous (Bi,Sb)@C electrode exhibits an ultralow capacity decay rate of merely 0.005% per cycle over 3200 cycles (equivalent to 1100 days) at 100 mA g −1 . This work establishes amorphous phase engineering as a general design paradigm, opening a decisive pathway toward durable, long‐life potassium‐ion batteries and potentially other energy storage systems facing similar stability challenges.
Advances in Wearable Bioimaging
ABSTRACT The development of wearable bioimaging platforms has accelerated in the era of precision medicine, addressing the limitations of conventional, facility‐based systems, which can be costly and difficult to access. In this review, we first outline the operating principles of major imaging modalities, with an emphasis on target tissues and factors that contribute to image quality. Next, we survey advances in miniaturizing these modalities into wearable devices, from electrical impedance tomography belts to flexible ultrasound and photoacoustic patches, highlighting materials selection and fabrication strategies that enhance image quality, skin adhesion, and functional integration. Lastly, we discuss outstanding technical and translational challenges that must be addressed to realize the full potential of these platforms, including safety and long‐term use. With sustained research and responsible commercialization, these wearable devices could reshape continuous physiological monitoring and enable more proactive, preventive health management.
All‐Optical Reconfigurable Physical Unclonable Function for Sustainable Security
ABSTRACT As security threats continue to evolve, static physical unclonable function (PUF) systems are facing inherent limitations in their security sustainability. This growing demand for sustainable security is driving a paradigm shift toward dynamic and reconfigurable PUF systems. However, previous approaches relying on thermal treatments to reconstruct physical entities can be limited in practicality due to concerns over thermal stability and scalability. Here, we present an all‐optical reconfigurable PUF that fills this unmet need through non‐invasive and scalable optical techniques. To demonstrate this, we introduce a nanopatterning method that employs plasmonic coupling‐induced sintering of optically trapped gold nanoparticles (AuNPs) to fabricate optical PUFs. The resulting PUFs, which leverage complex spatiospectral information, deliver practically sufficient security, outstanding encoding density, and robust resistance against machine learning‐based modeling attacks. Furthermore, we validate the applicability of the proposed PUF system for anti‐counterfeiting and traceability applications by implementing a lightweight authentication protocol that exhibits reliable performance. Lastly, we demonstrate that irreversible and on‐demand reconfiguration through optothermal nudging of patterned AuNPs enables repeated generation of unpredictable and independent responses while maintaining consistent security. These demonstrations signify the potential of our all‐optical approach as a promising pathway toward achieving sustainable hardware‐based security.
Synergistic modulation of cAMP and cGMP rescues hemin-induced plasma membrane fragmentation
Racial and ethnic disparities in hospital mortality among cancer patients admitted to the intensive care unit: A retrospective analysis of the MIMIC-IV database.
347 Background: Black patients with cancer face higher mortality rates than White patients across most malignancies, yet whether these disparities extend to the intensive care unit (ICU) setting remains poorly characterized. Prior ICU disparity studies have largely examined general critical care populations without accounting for cancer-specific factors such as tumor type and metastatic burden. We examined racial and ethnic disparities in ICU outcomes among cancer patients and assessed whether disparities differ by cancer type. Methods: We conducted a retrospective cohort study of adult cancer patients with ICU admissions in the MIMIC-IV database (v3.1; 2008-2022). Cancer diagnoses were identified using ICD-9/10 codes and classified as solid or hematologic. The primary outcome was hospital mortality. Sequential logistic regression models adjusted for demographics, insurance, cancer type, illness severity (SOFA, Charlson index), and admission characteristics, with White patients as the reference group. Stratified analyses were performed by cancer type and specific cancer site. Results: Among 14,399 ICU admissions, 72.3% were White, 9.7% Black, 4.4% Asian, and 3.0% Hispanic. Black patients were younger, had higher comorbidity burden, and were more likely to carry Medicaid insurance. Hospital mortality was 22.9% for Black vs 18.5% for White patients. In fully adjusted models, Black patients had persistently higher odds of hospital mortality (Table 1). The disparity was driven by solid tumors (OR 1.31; 95% CI 1.10-1.55; P=0.002) and absent in hematologic malignancies (OR 1.01; P=0.95). Prostate cancer showed the largest site-specific disparity (OR 2.26; 95% CI 1.32-3.88; P=0.003). Black patients had lower mechanical ventilation rates (23.8% vs 26.2%) and lower DNR/DNI documentation (6.5% vs 8.0%) despite higher mortality. Results were robust across five sensitivity analyses. Conclusions: Black patients with cancer admitted to the ICU had significantly higher hospital mortality than White patients even after comprehensive adjustment. This disparity was concentrated in solid tumors and was most pronounced in prostate and pancreatic cancers. The combination of higher mortality with lower intervention rates and less advance care planning documentation among Black patients warrants further investigation into potential mechanisms including treatment intensity differences and systemic care delivery inequities. Adjusted ORs for hospital mortality, Black vs White (sequential models). Model OR (95% CI) P-value Race only 1.31 (1.14-1.50) <0.001 +Demographics 1.34 (1.17-1.54) <0.001 +Insurance 1.33 (1.16-1.52) <0.001 +Cancer type 1.34 (1.17-1.54) <0.001 +Severity (SOFA, CCI) 1.28 (1.10-1.48) 0.001 +Admission characteristics 1.18 (1.01-1.36) 0.034
Expanding global access to oncology trials: mCODE-aligned AI for inclusive patient matching across literacy and resource settings.
18 Background: Clinical trial enrollment remains a global bottleneck in oncology. Despite therapeutic advances, only a minority of eligible patients enroll, largely due to fragmented electronic health records (EHRs), manual chart abstraction, and health literacy barriers. These limitations disproportionately affect patients in under-resourced settings and globally diverse populations. We evaluated an AI-powered platform designed to automatically extract oncology data from EHRs and structure them according to the Minimal Common Oncology Data Elements (mCODE) framework to enable scalable, interoperable trial matching. Methods: A fine-tuned GPT-4o model was developed to process structured and unstructured oncology EHR data. In a validation cohort of 102 patients (randomly sampled from a 3,800-patient oncology database), the system extracted tumor type, stage, disease extent, relapse status, resectability, and genomic biomarkers. Variables were mapped to mCODE 3.0 profiles (Cancer Disease Status, Tumor Characteristics, Genomics) and validated against expert chart review. Primary endpoints were accuracy (concordance) and completeness. Secondary endpoints evaluated interoperability and readiness for downstream clinical trial matching. Results: AI achieved high accuracy for tumor type (98%), extent of disease (90%), and stage (86%). Genomic extraction demonstrated 78% accuracy, reliably identifying common alterations including BRCA1/2 and TP53. Lower concordance in relapse status (77%) and resectability (69%) reflected documentation variability in free-text notes. All outputs were successfully structured within mCODE schemas. Compared with manual abstraction, AI reduced processing time substantially while maintaining clinical validity. Standardized outputs enabled seamless integration into multi-lingual, plain-language trial matching interfaces. Conclusions: AI-driven oncology data standardization aligned with mCODE enables scalable, real-time clinical trial matching across diverse health systems. By embedding interoperability at the data-extraction stage, this framework directly addresses structural and literacy-based barriers to trial access. These findings support the feasibility of AI-assisted infrastructure to democratize precision oncology research beyond geographic and language constraints.
Pre-existing antibody and T cell responses to SaCas9, AsCas12a and CasΦ are comparable in naïve individuals
Abstract Cas9 proteins are derived from human pathogens and are immunogenic, thereby raising potential safety concerns and limiting clinical effectiveness when using Cas9 as a gene-editing tool. Cas orthologs developed from organisms not directly associated with human infections may thus be safer. Here we compare the immunogenicity risk of SaCas9 (derived from the human pathogen, Staphylococcus aureus ), AsCas12a (derived from the human commensal, Acidaminococcus sp.) and CasΦ (derived from a bacteria phage, Biggiephage). Ex vivo and in vitro analyses show that SaCas9, AsCas12a and CasΦ are recognized similarly by antibodies and T cells from unimmunized individuals. Using mass-spectrometry to identify MHC-I-bound peptides, we find SaCas9, AsCas12a and CasΦ peptides presented on 9 MHC-I proteins commonly found in the North American population. Our results thus indicate that AsCas12a and CasΦ do not present a less immunogenic alternative to Cas9, and underscore the need for systematic immunogenicity evaluation of all Cas proteins intended for clinical use.